Working… Menu

Infigratinib in Recurrent High-Grade Glioma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04424966
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : December 31, 2020
Ivy Brain Tumor Center
Barrow Neurological Institute
QED Therapeutics
Information provided by (Responsible Party):
Nader Sanai, St. Joseph's Hospital and Medical Center, Phoenix

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : July 29, 2023